Clinicopathologic characteristics of cd99-positive diffuse large B-cell lymphoma

Acta Haematologica

Volumn 125, Issue 3, 2011, Pages 167-174

  Lee, Sang Pyo ^a   Park, Sanghui ^a   Park, Jinny ^a   Hong, Junshik ^a   Ko, Young Hyeh ^b  

^a Gachon University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Anaplastic carcinomas; CD99; Diffuse large B cell carcinomas; Germinal center B cells; Lymphomas

Indexed keywords

CD99 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PARAFFIN; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; FEMALE; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; IMMUNOREACTIVITY; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TISSUE MICROARRAY;

ANTIGENS, CD; CELL ADHESION MOLECULES; DISEASE-FREE SURVIVAL; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 78650635881     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322551     Document Type: Article

References (21)

1. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed 4. Lyon, International Agency for Research on Cancer, 2008.
2. Sung CO, Ko YH, Park S, Kim K, Kim W: Immunoreactivity of CD99 in non-Hodgkin's lymphoma: unexpected frequent expression in ALK-positive anaplastic large cell lymphoma. J Korean Med Sci 2005; 20: 952-956. (Pubitemid 43161858)
3. Hamilton G, Fellinger EJ, Schratter I, Fritsch A: Characterization of a human endocrine tissue and tumor-associated Ewing's sarcoma antigen. Cancer Res 1988; 48: 6127-6131.
4. Jung KC, Park WS, Bae YM, Hahn JH, Hahn K, Lee H, Lee HW, Koo HJ, Shin HJ, Shin HS, Park YE, Park SH: Immunoreactivity of CD99 in stomach cancer. J Korean Med Sci 2002; 17: 483-489.
5. Milanezi F, Pereira EM, Ferreira FV, Leitao D, Schmitt FC: CD99/MIC-2 surface protein expression in breast carcinomas. Histopathology 2001; 39: 578-583. (Pubitemid 34017130)
6. Yoo SH, Han J, Kim TJ, Chung DH: Expression of CD99 in pleomorphic carcinomas of the lung. J Korean Med Sci 2005; 20: 50-55. (Pubitemid 40342205)
7. Choi YL, Kim HS, Ahn G: Immunoexpression of inhibin alpha subunit, inhibin/activin betaA subunit and CD99 in ovarian tumors. Arch Pathol Lab Med 2000; 124: 563-569. (Pubitemid 30210989)
8. Gordon MD, Corless C, Renshaw AA, Beckstead J: CD99, keratin, and vimentin staining of sex cord-stromal tumors, normal ovary, and testis. Mod Pathol 1998; 11: 769-773. (Pubitemid 28381612)
9. Kommoss F, Oliva E, Bittinger F, Kirkpatrick CJ, Amin MB, Bhan AK, Young RH, Scully RE: Inhibin-alpha CD99, HEA125, PLAP,and chromogranin immunoreactivity in testicular neoplasms and the androgen insensitivity syndrome. Hum Pathol 2000; 31: 1055-1061.
10. Matias-Guiu X, Pons C, Prat J: Müllerian inhibiting substance, alpha-inhibin, and CD99 expression in sex cord-stromal tumors and endometrioid ovarian carcinomas resembling sex cord-stromal tumors. Hum Pathol 1998; 29: 840-845. (Pubitemid 28375991)
11. Hartel PH, Fanburg-Smith JC, Frazier AA, Galvin JR, Lichy JH, Shilo K, Franks TJ: Primary pulmonary and mediastinal synovial sarcoma: a clinicopathologic study of 60 cases and comparison with five prior series. Mod Pathol 2007; 20: 760-769. (Pubitemid 46933447)
12. Machen SK, Fisher C, Gautam RS, Tubbs RR, Goldblum JR: Utility of cytokeratin subsets for distinguishing poorly differentiated synovial sarcoma from peripheral primitive neuroectodermal tumour. Histopathology 1998; 33: 501-507. (Pubitemid 28563374)
13. Pan Y, Liu WP, Li JF, Zhang WY, Li FY, Lu XX, Li D, Li GD: A clinicopathological study of 96 cases of lymphoblastic lymphoma (in Chinese). Zhonghua Xue Ye Xue Za Zhi 2005; 26: 218-222.
14. Riopel M, Dickman PS, Link MP, Perlman EJ: MIC2 analysis in pediatric lymphomas and leukemias. Hum Pathol 1994; 25: 396- 399. (Pubitemid 24151126)
15. Robertson PB, Neiman RS, Worapongpaiboon S, John K, Orazi A: O13 (CD99) positivity in hematologic proliferations correlates with TdT positivity. Mod Pathol 1997; 10: 277-282.
16. Zhang PJ, Barcos M, Stewart CC, Block AW, Sait S, Brooks JJ: Immunoreactivity of MIC2 (CD99) in acute myelogenous leukemia and related diseases. Mod Pathol 2000; 13: 452- 458. (Pubitemid 30225236)
17. Buxton D, Bacchi CE, Gualco G, Weiss LM, Zuppan CW, Rowsell EH, Huang Q, Wang J: Frequent expression of CD99 in anaplastic large cell lymphoma: a clinicopathologic and immunohistochemical study of 160 cases. Am J Clin Pathol 2009; 131: 574-579.
18. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282. (Pubitemid 38029949)
19. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
20. Bernard G, Breittmayer JP, de Matteis M, Trampont P, Hofman P, Senik A, Bernard A: Apoptosis of immature thymocytes mediated by E2/CD99. J Immunol 1997; 158: 2543- 2550. (Pubitemid 127470509)
21. Park CK, Shin YK, Kim TJ, Park SH, Ahn GH: High CD99 expression in memory T and B cells in reactive lymph nodes. J Korean Med Sci 1999; 14: 600-606.